Zocor indications

List of indications
General Coronary Heart Disease Hyperlipidemia

General
Therapy with lipid-altering agents should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence of CHD, or other risk factors. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. Return to top

Coronary Heart Disease
In patients with coronary heart disease and hypercholesterolemia, ZOCOR is indicated to: Return to top
 * Reduce the risk of total mortality by reducing coronary death;
 * Reduce the risk of non-fatal myocardial infarction;
 * Reduce the risk for undergoing myocardial revascularization procedures;
 * Reduce the risk of stroke or transient ischemic attack.

Hyperlipidemia
patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb***). hyperlipidemia). type lll hyperlipidemia). hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. Return to top
 * ZOCOR is indicated to reduce elevated total-C, LDL-C, Apo B, and TG, and to increase HDL-C in
 * ZOCOR is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type lV
 * ZOCOR is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson
 * ZOCOR is also indicated to reduce total-C and LDL-C in patients with homozygous familial